Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...

Panelists stress that timely and accurate diagnosis of KMT2A-rearranged acute myeloid leukemia (AML) is essential for personalized treatment planning, highlighting the need to overcome systemic delays ...

SAN DIEGO — A polygenic score can link outcomes in Black pediatric patients with acute myeloid leukemia (AML) to genetic traits that arise more frequently in this population, new data reveal. The ...